An observational study in Maternal Complications, Pregnancy Complication and Birth Outcomes, Adverse, sponsored by Jazz Pharmaceuticals. Recruiting at 3 sites in 3 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Jazz Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Pregnancy Complications with a site in United States — 39 open to participants now, 47 under way, 1 of them phase 3. Pregnancy Complications · United States.
Among the 127 studies in Pregnancy Complications with a site in United States, this one is the 45th largest by planned enrollment of the 61 observational ones that give a count, is one of 17 that started in 2025, is one of 61 observational ones, reaches primary completion later than 44 of the 46 other live ones, and was the 92nd registered.
411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.
Browse Pregnancy Complications studies →39 of the 127 studies in Pregnancy Complications with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
University of Florida · Sites in United States
Ages 15–49 · Women only
Medicines360 · Sites in United States
Ages 18–99 · Women only · Healthy volunteers
Kenneth Moise MD · Sites in United States
Ages 18–45 · Women only
Michigan State University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 8 · Phase 4 6
First in 1995; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 400 across 198 observational studies indexed under Pregnancy Complications.
Median enrollment 96 across the 66 interventional studies, 477 across the 61 observational. Of the 69 that completed or were terminated, 19 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 127 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 1 study filed under Pregnancy Complications — fewer than ten, so there is no comparison to draw.
20 of the studies in Pregnancy Complications with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05552053Phase 3Cedars-Sinai Medical CenterResources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | 2026-12-31 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT06529042Mount Sinai Hospital, CanadaSCRIPT: Sickle Cell Risk in Pregnancy Tool | 2026-12 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06790043Albany Medical CollegeImpact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 127 studies in Pregnancy Complications with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.
Participants who were exposed to at least one dose of Epidiolex/Epidyolex during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
1) Patients exposed to a non-regulatory approved product containing Cannabidiol (CBD) during pregnancy who do not also have exposure to Epidiolex during the 13 days prior to their LMP or during the pregnancy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is no longer pregnant at the time of study enrollment.
Drug: Epidiolex
Participants who were exposed to at least one dose of Epidiolex/Epidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is pregnant at the time of study enrollment.
Drug: Epidiolex
Oral solution
Also known as: Epidyolex, Cannabidiol
Rate of MCM
Rate of Major congenital malformation (MCM) identified in the developing neonate and infant through 12 months of age
Time frame: Up to 12 months post birth
Rate of pregnancy outcomes
Rate of the following pregnancy outcomes: 1. Spontaneous abortion 2. Elective or therapeutic abortion 3. Fetal death/stillbirth 4. Molar or ectopic pregnancy 5. Preterm delivery 6. Live birth
Time frame: Up to 10 months gestation
Rate of other events of interest in the developing neonate and infant
Rate of the following other events of interest in the developing neonate and infant: 1. Hospitalizations for serious illness 2. Medications 3. Growth and development milestones 4. Neonatal or infant mortality 5. Inherited epilepsy syndrome
Time frame: Up to 12 months post birth
Rate of maternal complications during pregnancy
Rate of the following maternal complications during pregnancy: 1. Premature rupture of membranes (PROM) 2. Pre-eclampsia 3. Severe pregnancy-induced hypertension 4. Proteinuria 5. Gestational diabetes 6. Intrauterine growth restriction (IUGR) 7. Measures of fetal growth deficiency (small for gestational age)
Time frame: Up to 10 months gestation
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Aug 2033, 96 months after the start.
Of 121 observational studies under Pregnancy Complications, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 201. This study's planned 96 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.